Company intelligence / Profile preview
OncoOne
Vienna, Austriaoncoone.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
OncoOne is developing precision medicines targeting oxMIF for cancer and inflammatory diseases. The company has established laboratory capacity and partnerships for manufacturing monoclonal antibodies. They are currently seeking Series A+/B financing to advance their first programs into clinical trials.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodiesMulti-specific antibodiesADCsAntibody-based therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
GenScript ProBio (CDMO partnership)
Beyond the preview
Go deeper on OncoOne.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoOne.